Biomarin Pharmaceutical reported $27.66M in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acadia Pharmaceuticals ACAD:US $ -34.01M 79.04M
Acorda Therapeutics ACOR:US $ -46.68M 22.16M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
Amgen AMGN:US $ 1317M 159M
Bayer BAYN:GR € -298M 3589M
Biogen BIIB:US $ 1058M 754.2M
Biomarin Pharmaceutical BMRN:US $ 27.66M 93.13M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Gilead Sciences GILD:US $ 1144M 1125M
Insmed INSM:US $ -95645000 1.02M
Intercept Pharmaceuticals ICPT:US $ -7.53M 9.76M
IONIS PHARMACEUT IONS:US $ -65.17M 289.78M
Moderna Inc MRNA:US 2.2B 1.46B
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Ptc Therapeutics PTCT:US $ -152.09M 25.36M
Puma Biotechnology PBYI:US $ 9.37M 12.77M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Sangamo Biosciences SGMO:US $ -43.17M 0.8M
Sarepta Therapeutics SRPT:US $ -231.48M 126.46M
Seattle Genetics SGEN:US $ -134.83M 1.67M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
United Therapeutics UTHR:US $ 116M 123.9M
Vertex Pharmaceuticals VRTX:US $ 810.5M 48.4M
YTE INCY:US $ 161.43M 123.44M